{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG" in comments (approximate match)
Status:
US Approved Rx
(2008)
Source:
BLA125249
(2008)
Source URL:
First approved in 2008
Source:
BLA125249
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
First approved in 2008
Class:
PROTEIN
Status:
US Approved Rx
(2007)
Source:
BLA125166
(2007)
Source URL:
First approved in 2007
Source:
BLA125166
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2006)
Source:
BLA125151
(2006)
Source URL:
First approved in 2006
Source:
BLA125151
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
NDA021773
(2005)
Source URL:
First approved in 2005
Source:
NDA021773
Source URL:
Class:
PROTEIN
Conditions:
Exenatide (exendin-4) is sold under the brand name BYETTA to improve glycemic control in people with type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals but does not interfere with glucagon release in response to hypoglycemia.
Status:
US Approved Rx
(2005)
Source:
BLA125117
(2005)
Source URL:
First approved in 2005
Source:
BLA125117
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA021839
(2005)
Source URL:
First approved in 2005
Source:
BLA021839
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761268
(2022)
Source URL:
First approved in 2004
Source:
BLA125085
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA021106
(2003)
Source URL:
First approved in 2003
Source:
BLA021106
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA125058
(2003)
Source URL:
First approved in 2003
Source:
BLA125058
Source URL:
Class:
PROTEIN
